Biotech and healthcare look set to deliver eternal wealth, if not health


The recent sell-off in the listed biotech sector, following a strong 2003, has highlighted attractive buying opportunities for specialist hedge funds, according to managers in the niche strategy.

In the last 11 months of 2003, the MSCI World index outperformed the Dow Jones STOXX 600 Pharmaceuticals Biotechnology IG Price Index by 4.92%. However, the pharmaceutical and biotechnology index still posted healthy returns of 12.91%, according to Bloomberg, against MSCI World's 15.33%.

The rude

To continue reading...

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: